| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5291 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2759 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1657 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1329 | 2021 |
| Safety and efficacy of NVX-CoV2373 Covid-19 vaccine PT Heath, EP Galiza, DN Baxter, M Boffito, D Browne, F Burns, ... New England Journal of Medicine 385 (13), 1172-1183, 2021 | 948 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 739 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 739 | 2021 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 661 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 584 | 2021 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 330 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 269 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ... The lancet HIV 8 (8), e474-e485, 2021 | 216 | 2021 |
| Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis–infected Individuals CR Sander, AA Pathan, NER Beveridge, I Poulton, A Minassian, N Alder, ... American journal of respiratory and critical care medicine 179 (8), 724-733, 2009 | 152 | 2009 |
| Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions RO Payne, SE Silk, SC Elias, K Miura, A Diouf, F Galaway, H de Graaf, ... JCI insight 2 (21), 2017 | 137 | 2017 |
| Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer … S Toback, E Galiza, C Cosgrove, J Galloway, AL Goodman, PA Swift, ... The Lancet Respiratory Medicine 10 (2), 167-179, 2022 | 133 | 2022 |
| Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... Lancet 397 (10269), 99-111, 2021 | 133 | 2021 |
| Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a … APS Munro, S Feng, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, ... The Lancet Infectious Diseases 22 (8), 1131-1141, 2022 | 131 | 2022 |
| Use of an automated blood culture system (BD BACTEC™) for diagnosis of prosthetic joint infections: easy and fast AM Minassian, R Newnham, E Kalimeris, P Bejon, BL Atkins, ... BMC infectious diseases 14 (1), 1-7, 2014 | 119 | 2014 |
| A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Guérin AM Minassian, I Satti, ID Poulton, J Meyer, AVS Hill, H McShane Journal of Infectious Diseases 205 (7), 1035-1042, 2012 | 113 | 2012 |
| Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools AS De Groot, L Moise, F Terry, AH Gutierrez, P Hindocha, G Richard, ... Frontiers in Immunology 11, 442, 2020 | 104 | 2020 |
Helen McShaneThe Jenner Institute, University of OxfordVerified email at ndm.ox.ac.uk
